Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry

Table 4 Clinical outcomes data

Association between treatment modality and ventilator-free days	aIRR (95% CI)
Steroids	Reference
IL6-RAs
VFD (model 1)	1.12 (0.88, 1.40)
VFD (model 2 with highest FiO₂ added)	1.13 (0.90, 1.42)
VFD (model 2 with SOFA added)	1.12 (0.89, 1.40)
Target trial design (model 3)	1.13 (0.87, 1.45)
Combination therapy
VFD (model 1)	0.83 (0.60, 1.14)
VFD (model 2 with highest FiO₂ added)	0.88 (0.64, 1.20)
VFD (model 2 with SOFA added)	0.77 (0.56, 1.06)
Target trial design (model 3)	0.64 (0.34, 1.23)

Association between treatment modality and 28-day mortality	aOR (95% CI)
Steroids N = 583	Reference
IL6-RAs
28-day mortality (model 1) N = 168	0.68 (0.44; 1.07)
Hospital morality (model 1) N = 170	0.68 (0.43, 1.09)
28-day mortality (model 2) N = 170	0.7 (0.45, 1.08)
Target trial design (model 3) N = 121	0.6 (0.35, 1.03)
Combination therapy
28-day mortality (model 1) N = 104	1.07 (0.67, 1.70)
Hospital morality (model 1) N = 101	1.23 (0.72, 2.11)
28-day mortality (model 2) N = 101	1.21 (0.76, 1.93)
Target trial design (model 3) N = 35	1.96 (0.90, 4.28)

Missing data outcomes in sensitivity analysis (model 3): 4 patients had 28-day mortality status missing, and 15 patients had duration of iMV missing
Adjusted incident rate ratio (aIRR) was used for VFD (> 1 is favorable for intervention), Adjusted odds ratio (aOR) was used for 28-day mortality (< 1 is favorable for intervention)
aIRR adjusted incident rate ratio, aOR adjusted odds ratio, CI confidence interval, FiO₂ fractional inspired oxygen concentration, IL6-RAs interleukin-6 receptor antagonists, SOFA Sequential Organ Failure Assessment, VFDs ventilation-free days

ISSN: 2047-783X